2023 ACMG Annual Clinical Genetics Meeting Digital Edition: Poster Gallery-Feasibility and Initial Participation in Traceback Cascade Screening Programs for Ovarian Cancer Implemented at Three Integrated Health Systems

Pdf Summary

This study evaluates the feasibility and initial participation in traceback cascade screening programs for ovarian cancer implemented at three integrated health systems. The programs aim to identify patients with a history of ovarian cancer who did not receive genetic testing at the time of diagnosis and evaluate inherited cancer risk through retrospective outreach. The study finds that traceback programs are feasible and can identify opportunities for genetic testing. The overall uptake of participation in these programs is 23%, with Geisinger having a 13% uptake, Kaiser Permanente (KP) Mid-Atlantic States having a 37% uptake, and KP Washington having a 29% uptake. Each healthcare system designed and piloted its own traceback program, identifying patients through the Virtual Data Warehouse (VDW) Tumor Registry. Inclusion criteria included patients with a history of ovarian, fallopian tube, or peritoneal cancer diagnosed between 1974 and 2021 without electronic health record evidence of comprehensive genetic testing, while exclusion criteria included patients who did not meet NCCN clinical guideline criteria for genetic testing of inherited cancer risk. The study also finds that staff ability to order genetic testing may be associated with higher participation, while barriers to implementation include the need for manual electronic health record review to identify candidates for traceback programs, non-clinical staff calling patients, and the requirement for formal pre-test genetic counseling before arranging test ordering and sample collection. Overall, traceback cascade screening programs have the potential to increase the uptake of genetic testing in patients with ovarian cancer.

Asset Subtitle

Co-Author - Tracey Leitzel, BS; Co-Author - Alanna Kulchak Rahm, PhD, MS, CGC; Co-Author - Saumya Patel, BS; Co-Author - Rachel Schwiter, MS, CGC; Co-Author - Meredith Lewis, MS; Co-Author - Yirui Hu, PhD; Co-Author - M. Cabell Jonas, PhD; Co-Author - Pim Suwannarat, MD; Co-Author - Adrienne Deneal, MS; Co-Author - Sundeep Basra, MPH; Co-Author - Jennifer L. Brown, RHIT, CTR; Co-Author - Estella Khieu, BS; Co-Author - Elsa Balton, MS, CGC; Co-Author - Arvind Ramaprasan, MS; Co-Author - Kathleen A. Leppig, MD; Co-Author - Aaron Scrol, MS; Presenting Author - Nora B. Henrikson, PhD, MPH;

Meta Tag

Cancer Syndromes

Genetic Testing

Co-Author Tracey Leitzel, BS

Co-Author Alanna Kulchak Rahm, PhD, MS, CGC

Co-Author Saumya Patel, BS

Co-Author Rachel Schwiter, MS, CGC

Co-Author Meredith Lewis, MS

Co-Author Yirui Hu, PhD

Co-Author M. Cabell Jonas, PhD

Co-Author Pim Suwannarat, MD

Co-Author Adrienne Deneal, MS

Co-Author Sundeep Basra, MPH

Co-Author Jennifer L. Brown, RHIT, CTR

Co-Author Estella Khieu, BS

Co-Author Elsa Balton, MS, CGC

Co-Author Arvind Ramaprasan, MS

Co-Author Kathleen A. Leppig, MD

Co-Author Aaron Scrol, MS

Presenting Author Nora B. Henrikson, PhD, MPH

Keywords

traceback cascade screening programs

ovarian cancer

feasibility

genetic testing

inherited cancer risk

uptake of participation

healthcare systems

Virtual Data Warehouse

Tumor Registry

pre-test genetic counseling